Key terms

About ACET

Adicet Bio, Inc. is a clinical stage biotechnology company, which engages in discovering and developing allogeneic gamma delta T cell therapies for cancer. It also focuses on developing a pipeline of “off-the-shelf” gamma delta T cells. The company was founded by Aya Jakobovits in November 2014 and is headquartered in Boston, MA.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest ACET news

Mar 21 9:05am ET Adicet Bio (ACET) Receives a New Rating from Truist Financial Mar 20 12:26pm ET Adicet Bio: A Strong Buy on Robust Financials and Promising Clinical Trials Mar 20 10:55am ET Buy Rating Affirmed for Adicet Bio Amid Promising CAR T-Cell Therapies and Strong Financial Footing Mar 20 7:25am ET Adicet Bio’s Promising Drug Pipeline and Buy Rating Justification Mar 20 5:56am ET Buy Recommendation for Adicet Bio Amid Promising Autoimmune and Cancer Therapy Developments Mar 20 12:25am ET JMP Securities Keeps Their Hold Rating on Adicet Bio (ACET) Mar 19 4:13pm ET Adicet Bio reports Q4 EPS (69c), consensus (69c) Feb 13 2:02pm ET Adicet upgraded to Buy on cell therapy potential at JonesResearch Feb 13 1:56pm ET Adicet Bio upgraded to Buy from Hold at JonesResearch Feb 02 9:34am ET Adicet Bio price target lowered to $10 from $26 at H.C. Wainwright Jan 25 4:36am ET Adicet Bio Announces Offering Pricing and Cash Position Jan 25 4:36am ET Adicet Bio Launches Public Stock and Warrant Offering Jan 23 6:14am ET Adicet Bio 27.05M share Spot Secondary priced at $2.40 Jan 22 4:30pm ET Adicet Bio announces common stock offering, no amount given Jan 09 4:26pm ET JMP Securities Sticks to Their Hold Rating for Adicet Bio (ACET) Jan 07 5:28am ET Adicet Bio (ACET) Gets a Buy from BTIG Jan 05 7:29am ET Adicet Bio price target lowered to $19 from $21 at Canaccord Jan 04 12:25pm ET Buy Rating on Adicet Bio Backed by Strong Clinical Data and Strategic Focus on MCL Jan 02 9:10am ET BTIG Keeps Their Buy Rating on Adicet Bio (ACET) Dec 31 5:07am ET BTIG Sticks to Its Buy Rating for Adicet Bio (ACET)

No recent news articles are available for ACET

No recent press releases are available for ACET

ACET Financials

1-year income & revenue

Key terms

ACET Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

ACET Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms